Occupational dermatitis is the second most common occupational disease in Europe, with anotable prevalence among healthcare workers-approximately 20% of whom are affected.However, these figures may be underestimated due to underreporting. Despite the presumedscale of the problem, there is no recent European data providing real numbers. This studyseeks to address the knowledge gap regarding the impact of the COVID-19 pandemic onoccupational dermatitis within the healthcare workers population.EPIDERMAPS is a retrospective cohort study that analyzes data from two specializedcenters in the Paris region. The primary goal is to assess changes in the proportion ofdermatology-allergology consultations among healthcare workers before and after theCOVID-19 pandemic. Secondary objectives include evaluating the pandemic's effect onoccupational dermatoses incidences, attributed to increased PPE and hygiene productsusage. The major focus will be on work-related allergic contact dermatitis, irritantcontact dermatitis, contact urticaria, acne, and rosacea. The latter objective is toidentify new allergens or contributing factors.Participants include active healthcare workers aged 18 or older who sought consultationsfor dermatological or dermatology-allergology related motifs between March 15, 2017, andMarch 15, 2023. Exclusions apply for patients who have consulted for other thandermatology-allergology related motif and those opposing to participate. Data will bestored, anonymized, and analyzed using EasyMedStat. Data collection is scheduled betweenMarch and December 2024.This research aims to offer insights into COVID-19's dermatologic and allergic effects onhealthcare professionals, informing future preventive measures and enhanced carestrategies.
Occupational dermatoses include several dermatological conditions, the most common are
allergic contact dermatitis, irritant contact dermatitis, contact urticaria, acne, and
rosacea. Occupational dermatitis is the second most common occupational disease in
Europe, with a notable prevalence among healthcare workers-approximately 20% of whom are
affected. However, these figures may be underestimated due to underreporting. Despite the
presumed scale of the problem, there is no recent European data providing real numbers.
This study seeks to address the knowledge gap regarding the impact of the COVID-19
pandemic on occupational dermatitis within the healthcare workers population.
EPIDERMAPS is a retrospective cohort study that analyzes data from two Parisian centers
specialized in occupational dermatology and allergology - Centre Hospitalier
Intercommunal de Créteil and l'Hôpital Hôtel Dieu in Paris. Both centers are recognized
at the national level as the Occupational and Environmental Disease Consultation Center
(Centre de Consultation de Pathologies Professionnelles et de l'Environnement).
The primary goal is to analyze the impact of the COVID-19 on the proportion of
dermatology-allergology consultations of healthcare workers in relation to the total
number of consultations in these two centers, before and after the pandemic.
Secondary objectives include:
- Analysis of the impact of COVID-19 on the incidence of dermatoses induced by the
increased use of surgical masks and gloves, increased handwashing, and the
heightened use of hydro-alcoholic solutions and surface disinfectants among
healthcare personnel. The major focus will be on allergic contact dermatitis,
irritant contact dermatitis, contact urticaria, acne and rosacea.
- Analysis of the impact of COVID-19 on the contact allergic sensitization to
components of surgical masks, gloves, soaps, disinfectant cleansers, and
hydroalcoholic solutions among healthcare personnel.
- Identification of new allergens or new factors causing dermatoses among healthcare
personnel following the COVID-19 epidemic.
The Inclusion criteria require to be an active healthcare worker aged 18 or older at the
date of the first consultation. Further criteria are to have consulted for dermatological
or dermatology-allergology related motifs between March 15, 2017, and March 15, 2023.
Exclusions apply for non-healthcare workers, patients who have consulted for other than
dermatology-allergology related motif, and those opposing to participate. Patient
identification involves querying the National Network for Surveillance and Prevention of
Occupational Diseases (RNV3P, Réseau National de Vigilance et de Prévention des
Pathologies professionnelles). Eligible patients will be informed by mail, and if no
opposition expressed, their data will be collected and stored anonymously for analysis.
Patient data will be collected from medical records, anonymized, and stored securely.
Data collection is programmed from March to December 2024. The study comprises 471
patients from two centers.
The collected data will include:
- Age at the first consultation
- Date of the first consultation
- Date of birth (month and year)
- Gender
- Occupation
- Duration in the profession
- Diagnosed condition(s)
- Date of symptom onset
- Nature of symptoms
- Location of lesions
- Identified aggravating/triggering factors
- Professional rhythm of lesions
- History, such as:
- Atopic dermatitis
- Asthma
- Rhinoconjunctivitis
- Contact dermatitis
- Documented allergic sensitization to an allergen
- Urticaria
- Acne
- Rosacea
- Patch test results and their relevance
- Prick test results
- Socio-professional outcome (job accommodation, job change, career reorientation,
etc.)
Statistical analyses will use EasyMedStat to respond to the primary and secondary
objectives.
The study has been officially approved by the Local Ethics Committee (CEL) of Créteil on
the December 19th, 2023.
In conclusion, this research aims to provide new data on COVID-19's dermatologic and
allergic effects on healthcare professionals, informing future preventive measures and
enhanced care strategies.
Inclusion Criteria:
- Patients who consulted for the first time between 15th march 2017 and 15th march
2023 for an occupational dermato-allergological problem ;
- Active subjects and occupying a health personnel position defined according to the
Public Health Code ;
- Over 18 years old at the first consultation, with no upper limit
- Having not expressed their opposition to participate in the study.
Exclusion Criteria:
- Patients who consulted for an other problem than occupational dermato-allergological
problem ;
- Patients who not consulted for the first time between 15th march 2017 and 15th march
2023.
- Patients without occupational activity the day of the first consultation
- Patients who opposite to participation in the study
Hôpital Hôtel Dieu
Paris, France
Investigator: Lynda BENSEFA-COLAS, Dr
Contact: 0142348666
lynda.bensefa-colas@aphp.fr
Marie-Thérèse LE CAM, Dr
0157022074
marie-therese.lecam@chicreteil.fr
Camille Jung, Dr
0157022268
camille.jung@chicreteil.fr
Not Provided